Welcome to
Texas Biologics
Investing in disease prevention and treatment
Photo credit: NEXU
Programs
Through our innovative programs, Texas Biologics is investing in every phase of biologic development, from research support to clinical evaluation to commercialization.
Learn More
Current Projects
UT researchers are active in the development of new biologic therapies, including enzymes, antibodies, peptides and vaccines.
Learn More
Partner With Us
There are many ways to engage with Texas Biologics, from academic collaboration to technology licensing to philanthropic support.
Learn More
Home
First Science Studios Awardees Announced
In partnership with Dell Med’s HTRI, we awarded the first Science Studios awards. A major goal of the program is to connect clinician investigators at Dell Med with scientists across the UT campus to address outstanding questions in the medical sciences.
Read more about the 2023 awardees
100+
Patents since 2012
$750M
Raised via spinoff companies
12+
Drugs in commercial use or development
News
FDA-Approved RSV Vaccine Enabled by Work of UT Molecular Biologist
Every year, millions of people become sickened by RSV, and more than 100,000 die. New vaccines with a connection to UT Austin may help turn those numbers around.
Jason McLellan Receives Inaugural Award To Recognize Research Impact
A structural biologist at UT Austin who played a key role in the development of COVID-19 vaccines has received the first Research Impact Award.
The Achilles Heel That Could Lead to Universal Coronavirus Treatments
Alone, this target might not be strong enough to directly block infection, but might be used to jump-start or boost an immune response.
Texas Biologics in the Media
-
The Atlantic
-
First RSV vaccine with UT ties expected to be available by next year
KXAN
-
University of Texas research initiative to advance development of biologic therapies
Austin American-Statesman
